Shares of Repligen Corporation (NASDAQ:RGEN) rose 3.11% in premarket trading on Tuesday after the bioprocessing technology company reported third-quarter 2025 results that exceeded analyst expectations, supported by strong momentum across all business segments.
Repligen posted adjusted earnings of $0.46 per share, beating the consensus estimate of $0.42. Revenue surged 22% year over year to $189 million, well ahead of expectations of $181.78 million. Organic revenue growth reached 18% for the period, with no COVID-related contributions. All product franchises saw double-digit growth compared to the same quarter last year.
“We had another outstanding quarter in Q3 with 18% organic growth,” said Olivier Loeillot, President and CEO of Repligen. “We are thrilled with the momentum we are seeing across our broad, differentiated portfolio and the continued execution by our team.”
Growth was evenly spread, with both consumables and capital equipment revenue up more than 20%. The company recorded strong results across geographies, with Asia Pacific leading the regional performance. Revenues from both CDMO and biopharma segments increased by over 20%.
On the back of these results, Repligen raised its full-year 2025 guidance, now projecting revenue between $729 million and $737 million, representing 14%–15.5% year-over-year organic growth excluding COVID-related revenue. This compares favorably with the prior analyst consensus of $727.8 million.
The company expects adjusted EPS in the range of $1.65–$1.68, slightly below the $1.69 consensus. Adjusted EBITDA margin stood at 19.0% for the quarter, down from 20.7% in the prior year.